The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Diabetic nephropathy: diagnosis and treatment
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Dahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
Self-citationThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Adler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
Jamerson, K., Weber, M. A., Bakris, G. L., Dahlöf, B., Pitt, B., Shi, V., Hester, A., Gupte, J., Gatlin, M., & Velazquez, E. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806182 · Cited by 2,065
Microalbuminuria Predicts Clinical Proteinuria and Early Mortality in Maturity-Onset Diabetes
Mogensen, C. E. (1984) · New England Journal of Medicine · doi:10.1056/nejm198402093100605 · Cited by 1,908
Adler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W., Cull, C. A., Holman, R. R., & UKPDS Group (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00712.x · Cited by 1,816
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
Nrf2–Keap1 defines a physiologically important stress response mechanism
Motohashi, H., & Yamamoto, M. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.09.003 · Cited by 1,725
Pathologic Classification of Diabetic Nephropathy
Tervaert, T. W. C., Mooyaart, A. L., Amann, K., Cohen, A. H., Cook, H. T., Drachenberg, C. B., Ferrario, F., Fogo, A. B., Haas, M., de Heer, E., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010010010 · Cited by 1,690
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189
Reversal of Lesions of Diabetic Nephropathy after Pancreas Transplantation
Fioretto, P., Steffes, M. W., Sutherland, D. E. R., Goetz, F. C., & Mauer, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390202 · Cited by 1,135
Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy
Parving, H.-H., Persson, F., Lewis, J. B., Lewis, E. J., & Hollenberg, N. K. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708379 · Cited by 1,098
Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study
Andersen, A. R., Christiansen, J. S., Andersen, J. K., Kreiner, S., & Deckert, T. (1983) · Diabetologia · doi:10.1007/bf00284458 · Cited by 1,067
Mogensen, C. E., Neldam, S., Tikkanen, I., Oren, S., Viskoper, R., Watts, R. W., & Cooper, M. E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1440 · Cited by 1,037
Self-citationGæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 860
SGLT2 inhibition — a novel strategy for diabetes treatment
Chao, E. C., & Henry, R. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3180 · Cited by 822
Viberti, G., & Wheeldon, N. M. (2002) · Circulation · doi:10.1161/01.cir.0000024416.33113.0a · Cited by 802
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
Haller, H., Ito, S., Izzo, J. L., Januszewicz, A., Katayama, S., Menne, J., Mimran, A., Rabelink, T. J., Ritz, E., Ruilope, L. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007994 · Cited by 792
Renal and retinal effects of enalapril and losartan in type 1 diabetes
Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808400 · Cited by 791
Nephropathy in Patients with Type 2 Diabetes Mellitus
Ritz, E., & Orth, S. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910073411506 · Cited by 757
Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.
Shichiri, M., Kishikawa, H., Ohkubo, Y., & Wake, N. (2000) · PubMed · Cited by 727
de Zeeuw, D., Agarwal, R., Amdahl, M., Audhya, P., Coyne, D., Garimella, T., Parving, H.-H., Pritchett, Y., Remuzzi, G., Ritz, E., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61032-x · Cited by 695
The Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
The effect of proteinuria on relative mortality in Type 1 (insulin-dependent) diabetes mellitus
Borch-Johnsen, K., Andersen, P. K., & Deckert, T. (1985) · Diabetologia · doi:10.1007/bf00281993 · Cited by 598
Mahfoud, F., Schlaich, M., Kindermann, I., Ukena, C., Cremers, B., Brandt, M. C., Hoppe, U. C., Vonend, O., Rump, L. C., Sobotka, P. A., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.991869 · Cited by 573
Koya, D., Jirousek, M. R., Lin, Y. W., Ishii, H., Kuboki, K., & King, G. L. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119503 · Cited by 536
Graham, D. J., Ouellet-Hellstrom, R., MaCurdy, T. E., Ali, F., Sholley, C., Worrall, C., & Kelman, J. A. (2010) · JAMA · doi:10.1001/jama.2010.920 · Cited by 512
Avosentan for Overt Diabetic Nephropathy
Mann, J. F. E., Green, D., Jamerson, K., Ruilope, L. M., Kuranoff, S. J., Littke, T., & Viberti, G. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009060593 · Cited by 492
Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes
Niewczas, M. A., Gohda, T., Skupien, J., Smiles, A. M., Walker, W. H., Rosetti, F., Cullere, X., Eckfeldt, J. H., Doria, A., Mayadas, T. N., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011060627 · Cited by 485
Bolton, W. K., Cattran, D. C., Williams, M. E., Adler, S. G., Appel, G. B., Cartwright, K., Foiles, P. G., Freedman, B. I., Raskin, P., Ratner, R. E., et al. (2004) · American Journal of Nephrology · doi:10.1159/000075627 · Cited by 461
Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes
Epstein, M., Williams, G. H., Weinberger, M., Lewin, A., Krause, S., Mukherjee, R., Patni, R., & Beckerman, B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00240106 · Cited by 459
Krolewski, A. S., Laffel, L. M. B., Krolewski, M., Quinn, M., & Warram, J. H. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505113321902 · Cited by 452
Soulis-Liparota, T., Cooper, M., Papazoglou, D., Clarke, B., & Jerums, G. (1991) · Diabetes · doi:10.2337/diab.40.10.1328 · Cited by 447
Self-citationWANG, P. (1993) · The Lancet · doi:10.1016/0140-6736(93)90816-y · Cited by 446
Heusser, K., Tank, J., Engeli, S., Diedrich, A., Menne, J., Eckert, S., Peters, T., Sweep, F. C. G. J., Haller, H., Pichlmaier, A. M., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.140665 · Cited by 433
Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat
Degenhardt, T. P., Alderson, N. L., Arrington, D. D., Beattie, R. J., Basgen, J. M., Steffes, M. W., Thorpe, S. R., & Baynes, J. W. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00207.x · Cited by 378
Vallon, V., & Thomson, S. C. (2012) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020911-153333 · Cited by 376
on behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-1951-1 · Cited by 371
Microalbuminuria and the Risk for Early Progressive Renal Function Decline in Type 1 Diabetes
Perkins, B. A., Ficociello, L. H., Ostrander, B. E., Silva, K. H., Weinberg, J., Warram, J. H., & Krolewski, A. S. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080872 · Cited by 370
Circulating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes
Gohda, T., Niewczas, M. A., Ficociello, L. H., Walker, W. H., Skupien, J., Rosetti, F., Cullere, X., Johnson, A. C., Crabtree, G., Smiles, A. M., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011060628 · Cited by 356
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials
Calcutt, N. A., Cooper, M. E., Kern, T. S., & Schmidt, A. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2476 · Cited by 352
Self-citationThe ACE Inhibitors in Diabetic Nephropathy Trialist Group* (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-5-200103060-00009 · Cited by 343
Pirfenidone for Diabetic Nephropathy
Sharma, K., Ix, J. H., Mathew, A. V., Cho, M., Pflueger, A., Dunn, S. R., Francos, B., Sharma, S., Falkner, B., McGowan, T. A., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010101049 · Cited by 319
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes
Perkovic, V., Heerspink, H. L., Chalmers, J., Woodward, M., Jun, M., Li, Q., MacMahon, S., Cooper, M. E., Hamet, P., Marre, M., et al. (2013) · Kidney International · doi:10.1038/ki.2012.401 · Cited by 316
Self-citationOrchard, T. J., Secrest, A. M., Miller, R. G., & Costacou, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1860-3 · Cited by 313
The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes
Tuttle, K. R., Bakris, G. L., Toto, R. D., McGill, J. B., Hu, K., & Anderson, P. W. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2686 · Cited by 300
Chaturvedi, N. (2001) · UCL Discovery (University College London) · Cited by 299
Groop, P.-H., Cooper, M. E., Perkovic, V., Emser, A., Woerle, H.-J., & von Eynatten, M. (2013) · Diabetes Care · doi:10.2337/dc13-0323 · Cited by 294
Self-citationDiabetes Complications: The MicroRNA Perspective
Kantharidis, P., Wang, B., Carew, R. M., & Lan, H. Y. (2011) · Diabetes · doi:10.2337/db11-0082 · Cited by 289
New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes
Sandholm, N., Salem, R. M., McKnight, A. J., Brennan, E. P., Forsblom, C., Isakova, T., McKay, G. J., Williams, W. W., Sadlier, D. M., Mäkinen, V.-P., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002921 · Cited by 278
Forbes, J. M., Cooper, M. E., Thallas, V., Burns, W. C., Thomas, M. C., Brammar, G. C., Lee, F., Grant, S. L., Burrell, L. M., Jerums, G., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.11.3274 · Cited by 277
Self-citationLowering Blood Pressure Reduces Renal Events in Type 2 Diabetes
de Galan, B. E., Perkovic, V., Ninomiya, T., Pillai, A., Patel, A., Cass, A., Neal, B., Poulter, N., Harrap, S., Mogensen, C.-E., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008070667 · Cited by 271
Self-citationForbes, J. M., Thallas, V., Thomas, M. C., Founds, H. W., Burns, W. C., Jerums, G., & Cooper, M. E. (2003) · The FASEB Journal · doi:10.1096/fj.02-1102fje · Cited by 263
Self-citationMonami, M., Ahrén, B., Dicembrini, I., & Mannucci, E. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12000 · Cited by 259
Navaneethan, S. D., Nigwekar, S. U., Sehgal, A. R., & Strippoli, G. F. M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04750908 · Cited by 258
Zoungas, S., de Galan, B. E., Ninomiya, T., Grobbee, D., Hamet, P., Heller, S., MacMahon, S., Marre, M., Neal, B., Patel, A., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0959 · Cited by 256
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Livingstone, S. J., Charlton-Menys, V., DeMicco, D. A., & Fuller, J. H. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.03.022 · Cited by 255
Williams, M. E., Bolton, W. K., Khalifah, R. G., Degenhardt, T. P., Schotzinger, R. J., & McGill, J. B. (2007) · American Journal of Nephrology · doi:10.1159/000108104 · Cited by 253
Bilous, R., Chaturvedi, N., Sjølie, A. K., Fuller, J., Klein, R., Orchard, T., Porta, M., & Parving, H.-H. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-1-200907070-00120 · Cited by 252
Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes
Weber, M. A., Bakris, G. L., Jamerson, K., Weir, M., Kjeldsen, S. E., Devereux, R. B., Velazquez, E. J., Dahlöf, B., Kelly, R. Y., Hua, T. A., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.046 · Cited by 244
for the ORIENT study investigators, Imai, E., Chan, J. C. N., Ito, S., Yamasaki, T., Kobayashi, F., Haneda, M., & Makino, H. (2011) · Diabetologia · doi:10.1007/s00125-011-2325-z · Cited by 236
Kohan, D. E., Pritchett, Y., Molitch, M., Wen, S., Garimella, T., Audhya, P., & Andress, D. L. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010080869 · Cited by 236
Epidemiology of Diabetic Nephropathy
Reutens, A. T., & Atkins, R. C. (2011) · Contributions to Nephrology · doi:10.1159/000324934 · Cited by 235
Ekinci, E. I., Jerums, G., Skene, A., Crammer, P., Power, D., Cheong, K. Y., Panagiotopoulos, S., McNeil, K., Baker, S. T., Fioretto, P., et al. (2013) · Diabetes Care · doi:10.2337/dc12-2572 · Cited by 223
Factors Associated With Frequent Remission of Microalbuminuria in Patients With Type 2 Diabetes
Araki, S.-I., Haneda, M., Sugimoto, T., Isono, M., Isshiki, K., Kashiwagi, A., & Koya, D. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2983 · Cited by 216
Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes
Hovind, P., Rossing, P., Tarnow, L., Johnson, R. J., & Parving, H.-H. (2009) · Diabetes · doi:10.2337/db09-0014 · Cited by 215
Shimazaki, A., Kawamura, Y., Kanazawa, A., Sekine, A., Saito, S., Tsunoda, T., Koya, D., Babazono, T., Tanaka, Y., Matsuda, M., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.4.1171 · Cited by 214
Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and Microalbuminuria
Adler, S. G., Schwartz, S., Williams, M. E., Arauz-Pacheco, C., Bolton, W. K., Lee, T., Li, D., Neff, T. B., Urquilla, P. R., & Sewell, K. L. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09321209 · Cited by 204
Prevention and Treatment of Diabetic Renal Disease in Type 2 Diabetes: The BENEDICT Study
Remuzzi, G., Macia, M., & Ruggenenti, P. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121324 · Cited by 194
Effects of Fibrates in Kidney Disease
Jun, M., Zhu, B., Tonelli, M., Jardine, M. J., Patel, A., Neal, B., Liyanage, T., Keech, A., Cass, A., & Perkovic, V. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.049 · Cited by 189
Diabetic kidney disease with and without albuminuria
MacIsaac, R. J., & Jerums, G. (2011) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0b013e3283456546 · Cited by 189
Diabetic Nephropathy: Can Renoprotection Be Extrapolated to Cardiovascular Protection?
Opie, L. H., & Parving, H.-H. (2002) · Circulation · doi:10.1161/01.cir.0000028099.24188.c4 · Cited by 178
Sulodexide Fails to Demonstrate Renoprotection in Overt Type 2 Diabetic Nephropathy
Packham, D. K., Wolfe, R., Reutens, A. T., Berl, T., Heerspink, H. L., Rohde, R., Ivory, S., Lewis, J., Raz, I., Wiegmann, T. B., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011040378 · Cited by 171
FIORETTO, P. (1993) · The Lancet · doi:10.1016/0140-6736(93)92183-t · Cited by 167
Urinary MicroRNA Profiling in the Nephropathy of Type 1 Diabetes
Argyropoulos, C., Wang, K., McClarty, S., Huang, D. Y. C., Bernardo, J., Ellis, D., Orchard, T. J., Galas, D. J., & Johnson, J. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054662 · Cited by 166
Kelly, D. J., Zhang, Y., Hepper, C., Gow, R. M., Jaworski, K., Kemp, B. E., Wilkinson-Berka, J. L., & Gilbert, R. E. (2003) · Diabetes · doi:10.2337/diabetes.52.2.512 · Cited by 166
Rosolowsky, E. T., Ficociello, L. H., Maselli, N. J., Niewczas, M. A., Binns, A. L., Roshan, B., Warram, J. H., & Krolewski, A. S. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04271007 · Cited by 161
Device-Based Antihypertensive Therapy: Therapeutic Modulation of the Autonomic Nervous System
Krum, H., Sobotka, P. A., Mahfoud, F., Böhm, M., Esler, M., & Schlaich, M. P. (2011) · Circulation · doi:10.1161/circulationaha.110.971580 · Cited by 158
Ng, D. P. K., Tai, B. C., Koh, D. S. Q., Tan, K. W., & Chia, K. S. (2005) · Diabetologia · doi:10.1007/s00125-005-1726-2 · Cited by 157
Alter, M., Ott, I. M., von Websky, K., Tsuprykov, O., Sharkovska, Y., Relle, K., Raila, J., Henze, A., Klein, T., & Hocher, B. (2012) · Kidney & Blood Pressure Research · doi:10.1159/000341487 · Cited by 156
Renal and Cardiac Effects of DPP-4 Inhibitors – from Preclinical Development to Clinical Research
Hocher, B., Reichetzeder, C., & Alter, M. (2012) · Kidney & Blood Pressure Research · doi:10.1159/000339028 · Cited by 153
Mychaleckyj, J. C., Craven, T., Nayak, U., Buse, J., Crouse, J. R., Elam, M., Kirchner, K., Lorber, D., Marcovina, S., Sivitz, W., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1811 · Cited by 149
Lassila, M., Seah, K. K., Allen, T. J., Thallas, V., Thomas, M. C., Candido, R., Burns, W. C., Forbes, J. M., Calkin, A. C., Cooper, M. E., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000133025.23732.46 · Cited by 148
Self-citationMenne, J., Park, J.-K., Boehne, M., Elger, M., Lindschau, C., Kirsch, T., Meier, M., Gueler, F., Fiebeler, A., Bahlmann, F. H., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2101 · Cited by 138
Low HDL Cholesterol and the Risk of Diabetic Nephropathy and Retinopathy
Morton, J., Zoungas, S., Li, Q., Patel, A. A., Chalmers, J. P., Woodward, M., Celermajer, D. S., Beulens, J. W. J., Stolk, R. P., Glasziou, P., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0306 · Cited by 136
Interactions between Renin Angiotensin System and Advanced Glycation in the Kidney
Thomas, M. C., Tikellis, C., Burns, W. M., Bialkowski, K., Cao, Z., Coughlan, M. T., Jandeleit-Dahm, K. A. M., Cooper, M. E., & Forbes, J. M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010013 · Cited by 136
Self-citationKim, M.-J., Frankel, A., Donaldson, M., Darch, S. J., Pusey, C. D., Hill, P. D., Mayr, M., & Tam, F. W. K. (2011) · Kidney International · doi:10.1038/ki.2011.224 · Cited by 133
Lane, P. H., Steffes, M. W., & Mauer, S. M. (1992) · Diabetes · doi:10.2337/diab.41.5.581 · Cited by 125
Sánchez‐Lozada, L. G., Tapia, E., Soto, V., Ávila-Casado, C., Franco, M., Zhao, L., & Johnson, R. J. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm783 · Cited by 120
Mannose-Binding Lectin as a Predictor of Microalbuminuria in Type 1 Diabetes
Hovind, P. H., Hansen, T. K., Tarnow, L., Thiel, S., Steffensen, R., Flyvbjerg, A., & Parving, H. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1523 · Cited by 119
Östergren, J., Poulter, N. R., Sever, P. S., Dahlöf, B., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., et al. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e328310e0d9 · Cited by 116
Jenkins, A. J., Lyons, T. J., Zheng, D., Otvos, J. D., Lackland, D. T., McGee, D., Garvey, W. T., & Klein, R. L. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.810 · Cited by 114
Pezzolesi, M. G., Katavetin, P., Kure, M., Poznik, G. D., SKUPIEN, J. K., Mychaleckyj, J. C., Rich, S. S., Warram, J. H., & Królewski, A. S. (2009) · Diabetes · doi:10.2337/db09-0641 · Cited by 109
on behalf of the FinnDiane Study Group, Hansen, T. K., Forsblom, C. M., Saraheimo, M., Thorn, L. M., Wadén, J., Høyem, P., Østergaard, J. A., Flyvbjerg, A., & Groop, P. (2010) · Diabetologia · doi:10.1007/s00125-010-1742-8 · Cited by 108
Bonnet, F., & Cooper, M. E. (2000) · PubMed · Cited by 106
Self-citationNormoalbuminuric Diabetic Kidney Disease in the U.S. Population
Mottl, A. K., Kwon, K. S., Mauer, M. S., Mayer-Davis, E. J., Hogan, S. L., & Kshirsagar, A. V. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.09.010 · Cited by 101
Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects
Zoja, C., Corna, D., Nava, V., Locatelli, M., Abbate, M., Gaspari, F., Carrara, F., Sangalli, F., Remuzzi, G., & Benigni, A. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00376.2012 · Cited by 101
de Zeeuw, D., Akizawa, T., Agarwal, R., Audhya, P., Bakris, G. L., Chin, M. P., Krauth, M., Heerspink, H. J. L., Meyer, C. J., McMurray, J. J. V., et al. (2013) · American Journal of Nephrology · doi:10.1159/000346948 · Cited by 98
Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study)
Mäkinen, V., Tynkkynen, T., Soininen, P., Forsblom, C. M., Peltola, T., Kangas, A. J., Groop, P., & Ala‐Korpela, M. (2011) · Metabolomics · doi:10.1007/s11306-011-0343-y · Cited by 92
Urine Proteome Analysis May Allow Noninvasive Differential Diagnosis of Diabetic Nephropathy
Papale, M., Paolo, S. D., Magistroni, R., Lamacchia, O., Palma, A. M. D., Mattia, A. D., Rocchetti, M. T., Furci, L., Pasquali, S., Cosmo, S. D., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0345 · Cited by 89
Andersen, S., Brøchner‐Mortensen, J., Parving, H., & Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3296 · Cited by 84
Ferrannini, E., Veltkamp, S. A., Smulders, R. A., & Kadokura, T. (2013) · Diabetes Care · doi:10.2337/dc12-1503 · Cited by 81
Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes
FinnDiane Study Group, Tolonen, N., Forsblom, C. M., Thorn, L. M., Wadén, J., Rosengård‐Bärlund, M., Saraheimo, M., Feodoroff, M., Mäkinen, V., Gordin, D., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1541-2 · Cited by 80
Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats
Luippold, G. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg584 · Cited by 78
Prognostic Value of the Insertion/Deletion Polymorphism of the ACE Gene in Type 2 Diabetic Subjects
Hadjadj, S., Fumeron, F., Roussel, R., Saulnier, P., Gallois, Y., Ankotché, A., Travert, F., Khalil, C. A., Miot, A., Alhenc‐Gelas, F., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2079 · Cited by 75
Serum Concentration of Cystatin C and Risk of End-Stage Renal Disease in Diabetes
Królewski, A. S., Warram, J. H., Forsblom, C. M., Smiles, A. M., Thorn, L. M., SKUPIEN, J. K., Harjutsalo, V., Stanton, R. C., Eckfeldt, J. H., Inker, L. A., et al. (2012) · Diabetes Care · doi:10.2337/dc11-2220 · Cited by 68
Menne, J., Shushakova, N., Bartels, J., Kiyan, Y., Laudeley, R., Haller, H. G., Park, J.-K., & Meier, M. (2013) · Diabetes · doi:10.2337/db12-0534 · Cited by 68
Role of PPARγ in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential
Yang, J., Zhang, D., Li, J., Zhang, X., Fan, F., & Guan, Y. (2008) · Clinical Science · doi:10.1042/cs20070462 · Cited by 67
One year course of oral sulodexide in the management of diabetic nephropathy
Achour, A., Kacem, M., Dibej, K., Skhiri, H., Bouraoui, S., & May, M. E. (2005) · Journal of Nephrology · doi:10.1093/joneph/18.5.568 · Cited by 64
Sampson, M., & Drury, P. (1992) · Diabetes Care · doi:10.2337/diacare.15.5.609 · Cited by 57
Wong, M. G., Perkovic, V., Woodward, M., et al. (2012) · Kidney International · doi:10.1038/ki.2012.383 · Cited by 55
A Purpose-Synthesised Anti-Fibrotic Agent Attenuates Experimental Kidney Diseases in the Rat
Gilbert, R. E., Zhang, Y., Williams, S. J., Zammit, S. C., Stapleton, D., Cox, A. J., Krum, H., Langham, R. G., & Kelly, D. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047160 · Cited by 43
The Extinguished BEACON of Bardoxolone: Not a Monday Morning Quarterback Story
Tayek, J. A., & Kalantar‐Zadeh, K. (2013) · American Journal of Nephrology · doi:10.1159/000346950 · Cited by 36
Grossniklaus, H. E. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01717-8 · Cited by 27
GWAS of Diabetic Nephropathy: Is the GENIE out of the Bottle?
Böger, C. A., & Sedor, J. R. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002989 · Cited by 24
Correction: Urinary MicroRNA Profiling in the Nephropathy of Type 1 Diabetes
Argyropoulos, C., Wang, K., McClarty, S., Huang, D. Y. C., Bernardo, J., Ellis, D., Orchard, T., Galas, D. J., & Johnson, J. P. (2013) · PLoS ONE · doi:10.1371/annotation/37e647d5-1781-4edf-86a8-e3b533c32ad9 · Cited by 24
The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
Thomas, M. C., Jandeleit-Dahm, K. A. M., & Tikellis, C. (2012) · PPAR Research · doi:10.1155/2012/456529 · Cited by 22
Self-citationMeta-analysis confirms raised risk of bladder cancer from pioglitazone
Kermode-Scott, B. (2012) · BMJ · doi:10.1136/bmj.e4541 · Cited by 22
Statin Use in Patients with Diabetes and Kidney Disease: The Japanese Experience
Koya, D., & Campese, V. M. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.16261 · Cited by 19
Into the light? Diabetic nephropathy and vitamin D
Thomas, M. C., & Cooper, M. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61304-9 · Cited by 18
Self-citationBardoxolone improves kidney function in type 2 diabetes
Thomas, M. C., & Cooper, M. E. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.114 · Cited by 14
Self-citationEmerging drugs for managing kidney disease in patients with diabetes
Thomas, M. C. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.762356 · Cited by 10
Is diabetic nephropathy disappearing from clinical practice?
Cooper, M. E. (2006) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2006.00205.x · Cited by 7
Self-citation
Cited by
Epigenetics and epigenomics in diabetic kidney disease and metabolic memory
Kato, M., & Natarajan, R. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0135-6 · Cited by 600
The cardio-renal-metabolic connection: a review of the evidence
Marassi, M., & Fadini, G. P. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01937-x · Cited by 386
Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Opazo-Ríos, L., Mas, S., Marín-Royo, G., Mezzano, S., Gómez-Guerrero, C., Moreno, J. A., & Egido, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072632 · Cited by 363
Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease
Kikuchi, K., Saigusa, D., Kanemitsu, Y., Matsumoto, Y., Thanai, P., Suzuki, N., Mise, K., Yamaguchi, H., Nakamura, T., Asaji, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09735-4 · Cited by 298
Wang, Z., Sun, W., Li, R., & Liu, Y. (2022) · Bioengineered · doi:10.1080/21655979.2021.2023794 · Cited by 48
Metadata
- Authors
- Fineberg, D., Jandeleit-Dahm, K. A. M., & Cooper, M. E.
- Venue
- Nature Reviews Endocrinology
- Published
- 2013-10-08
- Volume
- 9
- Issue
- 12
- Pages
- 713-723
- ISSN
- 1759-5029 (ISSN-L)
- 1759-5037
- OpenAlex
- W1999575142
- Cited by
- 295
- References
- 144
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.